Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.76 |
| ▸ | MET | P08581 | 1/20 | 0.74 |
| ▸ | NQO2 | P16083 | 1/20 | 0.74 |
| ▸ | FECH | P22830 | 1/20 | 0.74 |
| ▸ | CLK3 | P49761 | 1/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417633 | 1.00 | PLK1 (0.76) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123171 | 0.91 | PLK1 (0.76) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123355 | 0.91 | PLK1 (0.76) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1122893 | 0.90 | PLK1 (0.74) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1122897 | 0.90 | PLK1 (0.74) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123045 | 0.89 | PLK1 (0.80) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123046 | 0.89 | PLK1 (0.80) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123003 | 0.88 | PLK1 (0.78) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL18437761 | 0.88 | PLK1 (0.72) | PLK1HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL1123005 | 0.88 | PLK1 (0.78) | PLK1HDAC4HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | claimed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | claimed |
| US-8324190-B2 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | CCNY, CCND2, ETV6 | PLK1 1292/4885HDAC4 2323/4885HDAC1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.